Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q1 2018 · 10-Q
Revenue$132.00K$132.00K+94.1% vs Q1 2017 Net Income-$21.55M-$21.55MN/M vs Q1 2017 EPS Diluted-$0.09-$0.09N/M vs Q1 2017 Operating Income-$8,816,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
Margins · derivedOperating margin-6678.8%+10827.1 pt vs Q1 2017
Net margin-16322.0%+2236.9 pt vs Q1 2017
ended Mar 31, 2018 · filed May 16, 2018 · 46 d after period end